Background: Cirrhosis is a common complication of chronic hepatitis B. It remains unclear if viral and biochemical parameters at baseline affect virological response to entecavir and therefore warrant investigation. In the present study, we aimed to evaluate the efficacy of entecavir therapy by monitoring virological response at the end of the 3 rd month of treatment and try to figure out whether baseline factors could help predict it in a cohort of hepatitis B virus (HBV) compensated cirrhosis patients and to determine the cut-off value of a predicting parameter. Methods: A total of 91 nucleos(t)ide-naïve patients with HBV induced cirrhosis (compensatory stage) were enrolled in a prospective cohort. HBV DNA and alanine aminotransferase (ALT) were tested at baseline and monitored every 3-6 months after starting therapy. Results: Of all 91 patients, the median follow-up time was 12 (9-24) months. Overall, 64 patients (70.3%) achieved virological response in the 3 rd month. Univariate analysis showed that the 3 rd month virological response can be predicted by baseline HBV DNA levels (P < 0.001, odds ratio [OR]: 2.13, 95% confidence interval [CI]: 1.44-3.15), ALT value (P = 0.023, OR: 1.01, 95% CI: 1.00-1.01) and hepatitis B e antigen (HBeAg) negativity (P = 0.016, OR: 0.30, 95% CI: 0.11-0.80). Multiple regression analysis showed baseline HBV DNA level was the only parameter related to full virological response. Higher baseline HBV DNA strata indicated a higher probability that HBV DNA remains detectable at the 3 rd month (P = 0.001). Area under receiver operating characteristic curve for determining the 3 rd month virological response by baseline HBV DNA was 77.6% (95% CI: 66.7-85.2%), with a best cut-off value of 5.8 log 10 . Conclusions: Baseline HBV DNA, HBeAg negativity, and ALT were independent factors contributing to virological response at the 3 rd month. Further, multiple regression showed that HBV DNA level was the only parameter predicting full virological response as early as the 3 rd month, in this cirrhosis cohort. compensated stage often remain asymptomatic for many years, allowing a normal quality of life. Thus, effective suppression of HBV replication to prevent disease prognosis is critical. Nucleos(t)ide analogs (NAs) have been proven to be effective at inhibiting HBV replication. [8, 9] Entecavir is a new potent NA. Cirrhosis patients who received entecavir treatment had a significantly lower liver-related death rate than the placebo group.
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IntroductIon
An estimate of 240 million people have been chronically infected with hepatitis B virus (HBV) worldwide. [1] Chronic liver injury and ongoing inflammation in chronic hepatitis B (CHB) can lead to cirrhosis. In East Asia, the respective 5-year cumulative incidences of cirrhosis in hepatitis B e antigen (HBeAg) negative and HBeAg positive patients were 13% and 8%, respectively. [2] A cirrhotic liver initially maintains normal liver functions (compensatory stage), but 15% of patients may progress into a decompensated stage in 5-year while 3.7% will develop hepatocellular carcinoma (HCC). [3] Studies that investigated risk factors for the advancement of CHB to cirrhosis found that prognosis or histological progression [4] [5] [6] is strongly related to HBeAg positivity, serum HBV DNA, and alanine aminotransferase (ALT) levels.
Further analyses showed that elevated HBV DNA level is a single risk factor for deteriorating liver functions in HBV-related cirrhosis and is strongly related to the advancement of cirrhosis from a compensatory to a decompensated stage and HCC. [4, 7] Patients within compensated stage often remain asymptomatic for many years, allowing a normal quality of life. Thus, effective suppression of HBV replication to prevent disease prognosis is critical.
Nucleos(t)ide analogs (NAs) have been proven to be effective at inhibiting HBV replication. [8, 9] Entecavir is a new potent NA. Cirrhosis patients who received entecavir treatment had a significantly lower liver-related death rate than the placebo group. [10] Entecavir therapy resulted in more frequent improvement in histology, virological response and biochemical normalization in both HBeAg positive and negative patients compared to lamivudine (LAM). [11, 12] The primary goal of antiviral therapy is to prevent progression of liver injury. An early virological response often offers a positive sign for achieving the therapeutic goal.
Although patients with the partial virological response at 3 rd month could continue entecavir therapy, the 3 rd month (12 weeks) posttreatment is an important time point for antiviral therapy in both surrogate marker and treatment practice. It is at this time point that primary nonresponders to NAs therapy will be identified based on HBV DNA level. [13] Thus, HBV DNA at the 3 rd month of treatment reflects if HBV replication is effectively inhibited. Moreover, an early response to antiviral therapy is important. One log 10 IU/ml or greater reduction of HBV DNA level from the baseline at the 3 rd month could indicate such a response. [14] In addition, the lower the HBV DNA level, the higher the probability of spontaneous seroclearance of HBeAg. [15] Studies [16, 17] suggested that early HBV DNA decrease is an important prognostic marker. A negative HBV DNA or a fall of 3 log 10 from baseline at the 3 rd month projects a 96% probability of negative HBV DNA at week 96 posttreatment.
However, the available data of treating HBV cirrhosis patients with entecavir are limited. Virological and biochemical, or other factors that contributed to virological response at the 3 rd month of treatment, have not been investigated.
In the present study, we aimed to evaluate the efficacy of entecavir therapy by monitoring virological response at the end of the 3 rd month of treatment and try to figure out whether baseline factors could help predict it in a cohort of HBV compensated cirrhosis patients and to determine the cut-off value of a predicting parameter.
Methods
Study design and patient inclusion
This was a retrospective cohort study. The data were extracted from the database of a prospective study into which HBV-induced cirrhosis patients were enrolled for antiviral therapy either by entecavir or LAM plus adefovir dipivoxil (ADV) in eight centers located in the mainland of China. The prospective study began in March 2012, and recruitment of subjects is still ongoing. The study was conducted in accordance with the ethics principles of the Declaration of Helsinki and it was approved by the Institutional Ethics Committee.
There are generic and brand name versions of NAs available in China. Selection of NAs was made jointly by patients and their attending physicians, in view of medical insurance coverage, in accordance with the Guideline of Prevention and Treatment for CHB of China. An early virological response was defined as HBV DNA undetectable at the 3 rd month. Individuals were all nucleos(t)ide-naïve before recruitment and started therapy at a dose of entecavir at 0. (3) HBV DNA levels were more than 1000 U/ml (5 × 10 3 copies/ml) for HBeAg-positive patients or 100 IU/ml (500 copies/ml) for HBeAg-negative patients.
Exclusion criteria included: (1) Decompensated cirrhosis: Patients with ascites, hepatic encephalopathy, gastrointestinal bleeding, and other complications of cirrhosis (such as spontaneous bacterial peritonitis); (2) allergy to NAs (such as entecavir, ADV, LAM); (3) reported liver disease: Alcoholic liver disease, autoimmune liver disease, heretic liver disease, drug-induced liver disease, nonalcoholic fatty liver disease, and other chronic liver diseases; (4) laboratory tests demonstrating that alpha-fetoprotein was >100 ng/ml or Cr >1.5 × upper limit of normal (ULN); (5) patients with any malignant tumor; (6) any complication of severe heart, lung, kidney, brain, blood diseases or other important organs diseases; (7) complicated to severe mental illness (such as depression, mania, epilepsy, schizophrenia); (8) pregnant and lactating women.
The selection flow of this study is shown in Figure 1 . In this cohort, 563 recruited individuals were diagnosed with HBV compensated cirrhosis and had been treated by entecavir continuously. In 563 patients, 188 had been followed for more than 9 months. Among them, 112 had a consecutive record of every 3 months before HBV DNA first became undetected (follow-up varied at every 3 or 6 month after HBV DNA was undetectable). Five individuals who lacked the baseline HBV DNA or ALT data were excluded. In addition, 3 patients with baseline ALT >10 × ULN were excluded because of the possibility of extrahepatic lithiasis. A total of 13 patients treated with LAM + ADV were excluded. Thus, the total number of patients included in the study was 91, all of whom were treated with entecavir.
Laboratory statistics
Alanine aminotransferase and HBV DNA copies were assayed in individual centers. HBV DNA at undetectable levels was defined by HBV DNA ≤500 copies/ml (100 IU/ml).
ULN of ALT was defined as 40 U/L. LSM was performed by Fibroscan (Echosens, Paris, France).
Statistical analyses
Statistics with recorded clinical and laboratory data of this study were analyzed using the Statistical Program for Social Sciences (SPSS 20.0 for MAC; SPSS Inc., Chicago, IL, USA). Data were presented as follows: (i) n (%) (ii) mean ± standard deviation (SD) (iii) median (range). Categorical variables were compared by Chi-square testing or Fisher's exact testing as appropriate. Continuous variables were compared by the two-sided Student's t-test or nonparametric test as appropriate. An undetectable HBV DNA level was imputed as 0 for analysis. All statistics were calculated within 95% confidential intervals (95% CI). All reported P values were two-tailed. Statistical significance was taken as P < 0.05.
results
Baseline characteristics
There were 91 intention-to-treat patients included who were followed for a median 12 (9-24) months. The majority of patients were 40-60 years old with a male preponderance. Among the 91 patients, 54.7% were HBeAg negative, and most of them achieved virological response in the first 3 months. Thirty-eight (41.8%) participants had normal ALT (≤40 U/L). Fifty-two patients had a PLT level <100 × 10 Table 1 ].
Regression analysis
Baseline factors that may be related to an early undetectable HBV DNA were analyzed by logistic regression [ Table 2] .
Baseline HBV DNA level was strongly related to virological response at the 3 rd month (P < 0.001, odds ratio [OR]: 2.13, 95% CI: 1.44-3.15). Sixty-four patients (70.3%) had HBV DNA undetected at the 3 rd month; 3 of them experienced virological breakthrough. The remaining 27 patients (29.7%) had detectable HBV DNA after the 3 rd month; 2 of the 31 patients experienced virological breakthrough after the virological response. The mean ± SD of HBV DNA was lower in early response patients than in late responders.
The ALT baseline value was also associated with early virological response (P = 0.023, OR: 1.01, 95% CI: 1.00-1.01). There were 33 individuals (86.8%) with normal ALT, who had HBV DNA undetected at the 3 rd month while 58.5% in patients with abnormal ALT. In addition, 62.9% of the patients in the early virological response group were HBeAg negative while 59.0% patients who were HBeAg positive had HBV DNA undetectable within 3 months (P = 0.016, OR: 0.30, 95% CI: 0.11-0.80). Age, gender, alcohol consumption, LSM, PLT, T-Bil, ALB, and PT between patients with HBV DNA undetected at the 3 rd month and after first 3 months were comparable (P > 0.05). Baseline ALT and HBV DNA level and HBeAg negativity were further tested by multiple logistic regression. HBV DNA level was the only significant factor that could predict early response (P < 0.001, OR: 1.98, 95% CI: 1.33-2.94).
Stratification of hepatitis B virus DNA levels and receiver operating characteristic curve
We then stratified patients into six groups using the baseline HBV DNA levels [ Figure 2] . We found that patients with elevated HBV DNA at baseline had a higher probability to remain HBV DNA positive at the 3 rd month (P < 0.001).
Median HBV DNA values among patients with baseline serum HBV DNA levels at <7, 7.0-7.9 and ≥8.0 log 10 strata were 0.0, 2.9, and 3.3 log 10 , respectively, at the 3 rd month. The higher baseline HBV DNA and the higher median HBV DNA remained at the 3 rd month. The median HBV DNA became 0.0 log 10 in all groups after the 3 rd month. Approximately, 68.2% of all the participants with HBV DNA >7.0 log 10 , had detectable HBV DNA at the 3 rd month, which was significantly higher than 22.2% (5.0-6.9 log 10 group) and 12.1% (<5.0 log 10 group) (P < 0.01). A 38.1% HBV DNA detectable rate in >7.0 log 10 group at month 6 was also significantly higher than 3.6% in <5.0 log 10 group (P = 0.003) and 6.5% in 5.0-6.9 log 10 group (P = 0.009). There were no significant differences at the 9 th and 12 th months.
According to the receiver operating characteristic (ROC) curve analysis in this study, the baseline HBV DNA area under the curve for predicting the 3 rd month virological response was 77.6% (95% CI: 66.7-88.5%) [ Figure 3 ]. A baseline HBV DNA level at 5.8 log 10 showed a best cut-off value with a sensitivity of 85.2% and specificity of 64.1% for predicting the virological response at the 3 rd month.
Finally, we calibrated the accuracy of the cut-off value of predicting the 3 rd month HBV DNA virological response [ Figure 4 ]. Median HBV DNA in groups with baseline HBV DNA <5.8 and ≥5.8 log 10 were at a respective 0.0 log 10 and 2.4 log 10 at the 3 rd month. About 8.9% of the 45 patients with lower baseline HBV DNA had detectable HBV DNA at the 3 rd month, compared to 50.0% in 46 patients with higher baseline HBV DNA (P < 0.001). At the 6 th month, 2.6% had sustained detectable HBV DNA in the low baseline HBV DNA group, whereas the level was 23.8% in high baseline HBV DNA patients (P = 0.008). There were no significant differences between two groups in subsequent months. 
dIscussIon
In this study, we investigated the relationship between several baseline parameters and virological response to ETV therapy by the 3 rd month among patients with HBV induced cirrhosis. There were two notable features in this prospective study: (1) Our cohort is exclusively composed of HBV-related cirrhosis patients who were at a compensatory stage, treatment naive and were selected under strict recruiting and exclusion criteria. (2) We report that the baseline HBV DNA level was the most important factor related to full virologic response at the 3 rd month, and we identified a cut-off value of baseline HBV DNA level for predicting antiviral response. To our knowledge, our study is the first one to establish this cut-off value for prediction.
Our univariate analysis found that patients with lower HBV DNA or negative HBeAg at baseline tended to have a higher probability to achieve a full virologic response at the 3 rd month. Our results are in line with previous studies. [13, 18, 19] However, multiple regression analysis only confirmed the baseline HBV DNA level as a sole factor related to the virological response. This highlights the importance of the baseline HBV DNA level in achieving early full virological response, reflecting the fact that a shorter treatment course is sufficient to decrease HBV DNA to undetectable levels.
We also evaluated the best cut-off value that can be used to predict the virological response at the 3 rd month. We found that a <5.8 log 10 baseline HBV DNA cut-off represented significantly higher likelihood to achieve virological response at the 3 rd month. This cut-off was lower than that calculated from CHB patients. [20] This can be explained by the fact that the median HBV DNA level is lower in HBV-related cirrhosis patients than CHB patients. There was no significant difference in the HBV DNA undetectable rate between groups that either had more or fewer HBV DNA copies than 5.8 log 10 at baseline after 6 months.
In this study, we also investigated the relationship between baseline ALT value and the 3 rd month full virological response. Patients with ALT ≤1 × UNL had a higher probability of achieving a full virological response within the first three months than patients with ALT >1 × UNL in this cohort. Once a chronic HBV-induced patient experienced HBeAg seroconversion, as did more than half of our cohort, serum HBV DNA level was significantly reduced. The patients who were HBeAg negative, accompanied by a reduction in HBV DNA and normal ALT, were referred to as inactive carriers. Our results showed that patients with normal ALT had lower HBV DNA at baseline and a lower baseline HBV DNA level was favored for achieving an early full virological response in our cohort as discussed above. [7, 21, 22] It appears that our results indicating that a baseline normal ALT is a favorable factor for early loss of detectable HBV DNA contradicted the previous reports, which showed an elevated ALT. For instance, a value >5 × UNL at baseline was more likely to have HBeAg seroconversion and better virological response in treated CHB patients. [23] [24] [25] However, the real difference is due to the varied cohorts. Our cohort exclusively consisted of cirrhosis patients, half of which were inactive carriers. The published cohorts primarily consisted of CHB patients. CHB patients can be variable and may be at two different phases: One phase having high HBV DNA but accompanied only by slightly elevated ALT, and the other phase having a medium HBV DNA level accompanied by significantly elevated ALT. It takes a shorter time course to promote a change to undetectable from the medium HBV DNA than from a high HBV DNA level. The principle was the same: A relatively lower baseline HBV DNA promoted an earlier virological response.
The relationship between LSM and HBV DNA kinetics in Chinese HBV-induced compensated cirrhosis remains to be established. Our study showed that patients with different LSM baseline levels showed no significant difference in early virological response.
Our data showed that the baseline HBV DNA level was the most effective factor related to an early full virological response to ETV therapy. The lower the HBV DNA at baseline, the earlier the virological response was in our cohort.
One limitation of our study was although the enrolled patients were clear clinical diagnosed by strict criteria and every routine 3-month follow-up, the total cases were still limited and relatively short follow-up, as it was launched in March 2012 and patient recruitment is currently ongoing. In addition, our strict criteria of recruiting and exclusion of patients may impede the extrapolation of results to a broader range of HBV induced cirrhosis patients, especially to those who had combined autoimmune liver disease, severe kidney or cardiovascular diseases, and human immunodeficiency virus infection. 10 ) by sort of best cut-off value. Number of patients followed is presented as n/N. The n represents HBV DNA detectable patients. N represents all patients followed at that month.
